Position Papers

26th February 2025

Proposals for a Critical Medicines Act: Call for Evidence

Since February 2024, EIPG has been a member of the CMA (Critical Medicines Alliance) and has attended the Forum, where the CMA illustrated the progress of its activities.
When the European Commission asked all stakeholders for feedback about the « Call for Evidence for an Initiative » document last January, EIPG prepared and submitted its considerations.

25th March 2024

Environmental Sustainability: The EIPG perspective

EIPG has started the preparation of a document that analyses the main critical areas of the entire production process of a medicinal product and sets out its position on the interventions considered a priority in a perspective of changes that will lead to the inclusion of new methods alternative material resources and will require new skills.

24th November 2023

The drug shortage situation – EIPG’s point of view

Everyone in industry agrees that problems of shortages are complex with no quick solutions. Several factors can be identified as being at the root of the shortage of medicines, some of which intersect with each other, mainly concerning aspects with technical, qualitative, regulatory, forecasting, supply, speculative and economic implications.